To explore potential mechanisms by which galantamine improves glycemic control and DN we measured circulating glucagon-like peptide-1 (GLP-1) levels, renal Na+/glucose cotransporter-2 (SGLT-2) protein, mRNA expression and urinary glucose levels. Here, SLC5A2 is linked to liver dysplastic nodule.